Eli Lilly completes acquisition of SGX

Global pharmaceutical company Eli Lilly has completed the acquisition of SGX, it emerged this week.

The deal, Eli Lilly said, will enable it to integrate the SGX structure-guided drug discovery platform with its own efforts in the field of drug discovery.

SGX will also give Eli Lilly access to FAST, which is a fragment-based, protein structure-guided technology.

“We are pleased to complete the acquisition of SGX and are excited to bring the scientific and technological expertise of SGX into Lilly’s research organisation,” said Dr Steven M Paul, executive vice-president of Lilly’s science and technology division.

He explained that the deal with allow combined resources to strengthen the biology capabilities of the enlarged company.

Earlier this week saw Elanco, a division of Eli Lilly, announce an agreement to acquire global rights to a dairy cow supplement, Posilac (sometribove).

It agreed the deal with the Monsanto Company to improve its product portfolio.